Soligenix (SNGX) EBIT Margin (2010 - 2024)
Soligenix's (SNGX) quarterly EBIT Margin came in at 74495.09% in Q2 2024, down 7370722.0% YoY from N/an in Q3 2023, and down 4017.96% on a QoQ basis from 1809.03% in Q1 2024.
Soligenix (SNGX) EBIT Margin (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of EBIT Margin data on file, last reported at 74495.09% in Q2 2024.
- Quarterly EBIT Margin fell 7370722.0% year-over-year to 74495.09% in Q2 2024, while the trailing twelve-month figure through Dec 2024 was 7907.7% (down 699058.0% YoY) and the FY2024 annual result came in at 7907.7%, down 699058.0% from the prior year.
- EBIT Margin declined to 74495.09% in Q2 2024, from 1809.03% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 297.76% in Q3 2020 to a low of 74495.09% in Q2 2024.
- A 5-year average of 5310.94% and a median of 1377.55% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 139298 bps — and 2024, when it slumped 7370722 bps.
- Tracing SNGX's EBIT Margin over 5 years: stood at 767.68% in 2020, then slumped by 113 bps to 1636.76% in 2021, then surged by 40 bps to 975.22% in 2022, then climbed by 10 bps to 873.27% in 2023, then slumped by 8431 bps to 74495.09% in 2024.
- The last three EBIT Margin figures came in at 74495.09% (Q2 2024), 1809.03% (Q1 2024), and 873.27% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 19.75% |
| 10 | Soligenix | 6.15 Mn | 6.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -74,495.09% |
| Mar 31, 2024 | -1,809.03% |
| Dec 31, 2023 | -873.27% |
| Sep 30, 2023 | -1,363.89% |
| Jun 30, 2023 | -787.87% |
| Mar 31, 2023 | -836.26% |
| Dec 31, 2022 | -975.22% |
| Sep 30, 2022 | -1,854.61% |
| Jun 30, 2022 | -1,485.00% |
| Mar 31, 2022 | -2,229.25% |
| Dec 31, 2021 | -1,636.76% |
| Sep 30, 2021 | -1,807.17% |
| Jun 30, 2021 | -1,391.21% |
| Mar 31, 2021 | -1,513.36% |
| Dec 31, 2020 | -767.68% |
| Sep 30, 2020 | -297.76% |
| Jun 30, 2020 | -556.88% |
| Mar 31, 2020 | -916.53% |
| Dec 31, 2019 | -166.93% |
| Sep 30, 2019 | -292.15% |